Logo
Contact Us
Banner

Nidanilimab

Products

Quote Request

Nidanilimab

Nidanilimab

Catalog No.: PC0076

Size: 1 mg,5 mg, 10 mg, 50mg, 100 mg

Description

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumor cells. Nidanilimab can be used in the research of non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

CAS No. 2171061-85-9
Appearance Liquid
Color Colorless to light yellow
Shipping Shipping with dry ice.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
In Vitro Nidanilimab (CAN04; 20 µg/mL; murine MC38 colon cancer cells) has glycoengineered to mediate an enhanced antibody-dependent cellular cytotoxicity (ADCC, EC50<1 nM).
Nidanilimab (20 µg/mL; murine MC38 colon cancer cells) blocks IL1α and IL1β signaling with IC50 values of 3.9 nM and 4.1 nM, respectively.
In Vivo Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Logo

As the scientific machine continues to turn, Alfa Cytology is committed to keeping pace. We continue to expand our services and improve our existing resources to help our customers accelerate their research and support their careers.

Company
Our Services
Our Products

Copyright © Alfa Cytology. All rights reserved.